CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Rigel Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: Rigel Pharmaceuticals | Rigel Pharmaceuticals, Inc. | Rigel Pharmaceuticals, Inc., Chief Medical Officer | RIGEL PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Jul 1, 2005

First marketed drug

Apr 17, 2018

First NDA

Apr 17, 2018

Last known activity

Oct 31, 2025

Timeline

1990s

  1. Jul 1, 1996

    Rigel Pharmaceuticals— Founded

2020s

  1. Dec 1, 2022

    olutasidenib— Marketing Organization

  2. Dec 1, 2022

    olutasidenib— NDA Organization

  3. Dec 1, 2022

    olutasidenib— NDA Secondary Org

Drugs by trial phase (20 distinct, 38 trials)

Phase 3 (1 own, 0 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Recent trials (50)

Details

Founded
South San Francisco, CA, US Jul 1, 1996
First NDA
Apr 17, 2018
Last known activity
Oct 31, 2025

Designations held

  • Orphan drug